SKN | Scribe Therapeutics Prices Upsized $129 Million IPO at Top of Range to Advance CRISPR Heart Disease Therapies
Scribe Therapeutics, a clinical-stage biotechnology company developing CRISPR-based genetic therapies for cardiovascular disease, has priced an upsized initial public offering (IPO), raising approximately $129...
SKN | American Battery Materials Inc. Targets Critical Minerals Growth With Market Debut Plans
American Battery Materials Inc. is positioning itself within the rapidly expanding critical minerals sector as investor attention increases around lithium supply chains and the...
SKN | Tarsier Pharma Ltd. Advances Rare Eye Disease Treatments as Investors Watch Biotechnology Growth Potential
Tarsier Pharma Ltd. is attracting attention as the clinical-stage biotechnology company advances its pipeline of therapies targeting rare ophthalmic diseases and explores opportunities to...
SKN | Defense Technology Firm Lyntris Files for Estimated $300 Million IPO to Expand Military Connectivity Solutions
Lyntris, a defense technology company specializing in connectivity solutions for military operations, has filed with the U.S. Securities and Exchange Commission (SEC) for an...
SKN | Alpha Architect Launches US Equity 4 ETF as New Nasdaq-Listed Investment Vehicle
Alpha Architect has launched the Alpha Architect US Equity 4 ETF (Nasdaq: AAUB), a newly listed exchange-traded fund designed to provide investors with exposure...